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Abstract
Phenotypic screens can identify molecules that are at once penetrant and active on the integrated circuitry of a whole cell
or organism. These advantages are offset by the need to identify the targets underlying the phenotypes. Additionally,
logistical considerations limit screening for certain physiological and behavioral phenotypes to organisms such as zebrafish
and C. elegans. This further raises the challenge of elucidating whether compound-target relationships found in model
organisms are preserved in humans. To address these challenges we searched for compounds that affect feeding behavior
in C. elegans and sought to identify their molecular mechanisms of action. Here, we applied predictive chemoinformatics to
small molecules previously identified in a C. elegans phenotypic screen likely to be enriched for feeding regulatory
compounds. Based on the predictions, 16 of these compounds were tested in vitro against 20 mammalian targets. Of these,
nine were active, with affinities ranging from 9 nM to 10 mM. Four of these nine compounds were found to alter feeding.
We then verified the in vitro findings in vivo through genetic knockdowns, the use of previously characterized compounds
with high affinity for the four targets, and chemical genetic epistasis, which is the effect of combined chemical and genetic
perturbations on a phenotype relative to that of each perturbation in isolation. Our findings reveal four previously
unrecognized pathways that regulate feeding in C. elegans with strong parallels in mammals. Together, our study addresses
three inherent challenges in phenotypic screening: the identification of the molecular targets from a phenotypic screen, the
confirmation of the in vivo relevance of these targets, and the evolutionary conservation and relevance of these targets to
their human orthologs.
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Introduction
Before the molecular biology era, pharmacological targets were
typically classified by the effects of organic molecules on whole
tissues [1]. Many pathways were first recognized based on
phenotypic responsiveness to compounds without knowledge of
underlying molecular mechanisms. Examples include the inference
of the a- and b-adrenergic pathways in the 1940s [2], the inference
of the H2 histaminergic receptor [3] and of the m, and k-opioid
receptors in the 1970s [4], and the proposal of the 5-HT3
serotonergic receptor in the mid-1980s [5]. Although these targets
were eventually characterized by molecular biology, the tissue and
organism approach had the advantage that the compounds
emerging from it were active on a physiologically intact tissue or
organismal circuit, and directly linked functional perturbation of
targets to biological effects.
Phenotypic compound screens return to this classical approach
to capture some of the same advantages for the discovery of
molecules with systemic activity. Such screens have generally
relied on high content microscopy assays in cell-based systems [6–
8]. However, certain biological processes such as physiology and
behavior are the result of integrated organism-wide processes that
only manifest themselves in intact multicellular organisms. For
example, as a physiological process, feeding behavior is the
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outcome of integration of extrinsic and intrinsic cues of food
availability and energy demand and thus is best understood when
studied in whole organisms. Elucidation of the neural circuits that
determine feeding is a fundamental challenge in the neuroscience
of energy homeostasis [9]. Small molecules that alter feeding
behavior can serve as useful reagents for investigating these circuits
and provide exquisite temporal control in ways not easily achieved
through genetic manipulations.
Given their small size and ease of manipulation, C. elegans have
been used in pharmacology-based phenotypic screens [10–14].
These animals are also well suited for study of molecular and
neural circuits that underlie food intake behavior. C. elegans feeds
using peristaltic contractions of a muscular pharynx to aspirate
microbes into the lumen of the intestine [15]. This pharyngeal
pumping rate directly correlates with the transport of nutrients
into the intestinal lumen [16,17]. C. elegans’ central nervous system
integrates signals from external cues such as food availability, food
quality, and internal nutritional status to regulate feeding behavior
[17–20]. Multiple pathways in the nervous system that are
dependent on serotonin, glutamate, and neuropeptide release
regulate the pharyngeal pumping rate in C. elegans [21–27]. Thus,
C. elegans’ feeding behavior is subject to regulation by some of the
same physiological parameters and molecular components as those
in mammals.
Feeding behavior is a relatively challenging read-out for a
screen-scale phenotypic effort. Therefore, we focused on surrogate
phenotypes that could potentially enrich for identification of
feeding regulatory compounds. From a high-content microscopy
assay, we previously discovered 84 compounds, which increased or
decreased Nile Red in C. elegans [11]. Nile Red is a vital dye that
has been broadly used for detecting fat levels in numerous
experimental systems [28–32]. However, its use as a read-out of fat
content in C. elegans has been challenged [33–36]. Nevertheless, for
a subset of compounds emerging from the initial Nile Red screen,
effects on lipid content were further verified by other vital dyes,
biochemical methods, molecular read-outs of fat content, as well as
efficacy in mammalian cell-based models of adipogenesis [11].
Therefore, we hypothesized that compounds emerging from the
Nile Red screen would be enriched for those that also alter feeding
behavior.
For all but one of the compounds, no biological targets were
previously known. To predict targets for these compounds, we
used chemoinformatic inference based on ligand patterns
against mammalian receptors. For a subset of the predictions,
we tested the compounds against the predicted mammalian
targets in vitro and subsequently tested orthologs of these targets
in C. elegans by chemical-genetic epistasis. We then combined the
compounds with the mutants to map epistasis relationships for
feeding behavior, identifying four signaling pathways previously
unassociated with C. elegans feeding regulation. Together, our
findings reveal that chemical screens in C. elegans lead to
molecules with activity toward known human targets and
highlight the utility of C. elegans for unambiguous assessment
of compound–target–phenotype relationships in the context of
an intact organism.
Results
C. elegans Screen Actives Are Similar to Ligands for
Multiple Mammalian Targets
Computational chemoinformatics methods have been used to
query annotated ligand–target interactions to identify novel targets
for known drugs [37] and, recently, targets for ligands identified by
a screen in zebrafish [38]. We used the Similarity Ensemble
Approach (SEA) [39] to interrogate the ChEMBL database for
targets, represented by their ligand sets, resembling compounds of
the 84 identified in a C. elegans phenotypic screen [11]. ChEMBL
annotates more than 8,000,000 ligand–target interactions for
2,456 targets; mostly, mammalian. SEA uses extended connectiv-
ity fingerprints to measure chemical similarity, quantified as
Tanimoto coefficients (Tc), between a query molecule and each
target ligand. The ensemble of all pairwise Tc’s for a target’s ligand
set to the query are summed and compared to an expectation of
random association. Using statistical machinery similar to BLAST,
an expectation value (E-value) quantifies the possibility that
observed structural similarities could occur by chance. Because
SEA relies on reported ligand–target interactions, it cannot predict
associations for chemically novel molecules or for targets for which
no ligands have been identified. Nevertheless, SEA provides a
rapid and systematic approach for discovering the pharmacolog-
ical relevance of C. elegans actives vis-à-vis mammalian targets with
known ligands.
At an E-value threshold of less than 1025, 79 of the 84 active
compounds were associated with at least one target in ChEMBL.
Most compounds were predicted to have two or more targets, with
572 distinct targets predicted overall (Figure 1A). Target
predictions often spanned two or more classes per compound as
has been observed in GPCR pharmacological relationships [40].
We first considered the possibility that the profile of predicted
targets simply recapitulates the underlying distribution of target
classes in ChEMBL. This was not the case. Our ChEMBL-derived
dataset is composed of 35% enzymes, 15% ion channels, 30%
membrane receptors, and 20% transporters, transcription factors,
and other proteins. Conversely, more than 60% of the SEA-
predicted targets for the phenotypic actives were enzymes, whereas
both membrane receptors and ion channels were comparatively
underrepresented (Figure 1B). This deviation may reflect the
targets with known ligands that are relevant to metabolic
phenotypes or peculiarities of the C. elegans model, a question that
we will address below.
Author Summary
Many beneficial pharmacological interventions were first
discovered by observing the effects of perturbation of
intact biological systems by small organic molecules
without a priori knowledge of their targets. This forward
pharmacological approach has the advantage of directly
identifying new pharmacological agents that are active on
complex biological processes. However, because of exper-
imental feasibility, systematic application of this approach
is generally limited to small animals such as the round-
worm C. elegans and zebrafish, raising the question of
whether use of these animals could identify compounds
that act on ortholgous mammalian targets. A significant
challenge in addressing this question is the determination
of the molecular identities of the compounds’ targets
responsible for the desired phenotypic outcomes. Here we
describe a computational approach for target identifica-
tion based on structural similarities of newly identified
compounds to known ligand interactions with mostly
mammalian targets. For several of the compounds
emerging from a C. elegans phenotypic screen, we predict
and confirm mammalian targets using in vitro binding
assays. Using genetic and pharmacological assays, we then
demonstrate that a subset of these compounds alter C.
elegans feeding rates through the C. elegans counterparts
of the predicted mammalian targets.
Prediction & Testing of C. elegans Feeding Targets
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Testing SEA Predictions of Mammalian Targets in Vitro
To test the SEA predictions, we assayed selected molecules in
vitro against their putative mammalian targets. Given the many
potential ligand–target interactions (79 ligands on 572 targets,
1,024 overall pairs), we only tested compound–target interactions
for which established assays were readily accessible. We tested 16
different compounds against 20 targets (21 ligand–target pairs)
ranging from G-protein coupled receptors (GPCRs) and nuclear
hormone receptors (NHRs) to kinases and phosphatases (Figure 2,
Table S1). Nine compounds had significant activity at a 10 mM
assay concentration against nine predicted targets, including the
dopamine, tachykinin, oxytocin, and metabotropic glutamate
receptors, the Flt-3 receptor tyrosine kinase, PI3-kinases, and the
NHRs peroxisome proliferator activator receptor-gamma (PPAR-
c) and the androgen receptor (Figure 2). Significant activity was
not observed for 12 target–ligand predictions in vitro (Table S1). A
final ligand–target prediction did not show activity on the human
receptor in vitro, but was confirmed by chemical-genetic epistasis in
C. elegans (below). This 43% in vitro hit rate resembles that observed
for chemoinformatic linkage of human drugs to new [37] and to
adverse drug reaction targets [41].
The potencies of the hits ranged from 8.6 nM to 9.8 mM in full
concentration response analysis (Figure 2, Figures S1, S2, S3). As
expected, there was no correlation between E-value and potency,
since target affinity is not considered when calculating ligand
similarities. In several cases, SEA successfully predicted the overall
target family but not the exact isoform. For instance, H6 and B16
were predicted to antagonize tachykinin receptor–3 (Tkr-3) and
metabotropic glutamate receptor 5 (mGluR-5), respectively, but
instead antagonized Tkr-1 and mGluR-8 (Figure 2). Indeed,
compared to other mGluR antagonists, B16 appears to be
uniquely specific for the mGluR8 isoform (Table S2).
Identification of C. elegans Feeding-Regulatory
Compounds
To search for feeding regulatory compounds whose SEA-
predicted targets could be confirmed by direct testing against
mammalian targets in vitro, we focused on the compounds listed in
Figure 2. We found that B16, H6, F15, and D20 each increased
the pharyngeal pumping rate (Figure 3A). Our standard assay for
pharyngeal pumping rate is a real-time assay over a short time
interval (10 s), in which contractions of the posterior bulb of the
pharynx are manually counted. The rapid assay is particularly
amenable to measuring pumping rate in large numbers of animals
and experimental conditions. However, to alleviate concerns that
the short duration of the assay may capture an unrepresentative
aspect of the pumping rate, we compared its results with those
obtained over a longer time course (60 s) using time-lapse
microscopy (Figure S4, Movies S1, S2, S3, S4, S5). The long
time course study revealed that for young, egg-laying gravid adults
foraging on E. coli OP-50 lawns, the C. elegans pharynx contracts
almost continuously with occasional brief pauses of less than a
second, similar to that seen during short-term measurements.
Importantly, the results of the long-term video measurements
confirmed our short-term manual protocol that B16, H6, F15, and
D20 all increase pharyngeal pumping in a range of 7%–12%. The
percent increase in pharyngeal pumping rate caused by these
compound treatments is within the physiological range C. elegans
exhibits in response to food following a fast, or that reported with
animals treated with serotonin [17,27], one of the best character-
ized modulators of C. elegans pharyngeal pumping. While reduced
pharyngeal pumping could reflect deleterious effects on animal
health such as a general disruption of neuromuscular junctions,
increased pumping is less likely to be due to such nonspecific
effects.
To determine whether the feeding increasing effects of B16, H6,
F15, and D20 were dependent on specific developmental stages,
we evaluated their effects when administered at different
developmental exposure times (Figure 3B). C. elegans treated with
compounds beginning at the first larval stage (L1) assayed as L4
animals exhibited similar percentage increases in feeding in
response to B16, H6, F15, and D20 as animals that were allowed
an extra day under treatment then assayed as adults. L4 animals
do have a basal pumping rate that is lower than adults, and this is
reflected in different absolute pump counts for the two stages
Figure 1. Overview of the ligand-target predictions for C.
elegans screen actives. (A) Distribution of ligand predictions per
compound expressed as a histogram. (B) Target classes more frequently
(positive %) or less frequently (negative %) predicted for C. elegans
screen actives, using predictions on ChEMBL’s ligands as a baseline.
Data are calculated based on ligand–target interactions at a minimum
significance threshold of E,0.00001.
doi:10.1371/journal.pbio.1001712.g001
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(Figure 3B). Developmental exposure to the compounds was not
required to elevate the pumping rate, since day 1 gravid adults
raised without compound exposure still exhibited elevated
pumping once exposed to these compounds. The feeding elevating
effects of B16, D20, and F15 were notable within 1 h of exposure
but that of H6 required ,16 h (Figure 3B).
Pharmacological Similarity Predictions Identify Feeding
Regulatory Genes in C. elegans
To ascertain whether the feeding increasing compounds
mediated their effects through the targets identified in Figure 2,
we used genetic epistasis to test target engagement in vivo. We first
examined compound D20, which was predicted and shown in vitro
to act on the human Flt-3 receptor tyrosine kinase, a member of
the PDGF-b receptor superfamily that is involved in the early
stages of hematopoiesis and is active in certain cancers [42]. While
C. elegans do not have hematopoiesis, their genome encodes dozens
of tyrosine kinase domains with sequence similarity to the human
Flt-3 receptor with no one sequence being an obvious candidate
(Table S3). To determine whether D20 interacted with any of
these kinase domains to regulate feeding, we measured the
pharyngeal pumping rates of RNAi-treated populations, treated
with either D20 or DMSO as a vehicle control. We reasoned that
if D20 exerts its effects through a receptor tyrosine kinase in C.
elegans, inactivation of such a receptor should mimic the effects of
D20 on feeding and, importantly, render pharyngeal pumping
insensitive to further modulation. In contrast, combined pharma-
cological and genetic perturbations that act through independent
Figure 2. SEA predictions that were confirmed by in vitro testing.
doi:10.1371/journal.pbio.1001712.g002
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pathways will exhibit additive or synergistic effects on feeding
when combined.
For each of 26 receptor tyrosine kinases with significant BLAST
similarity to the Flt-3 receptor, we examined the effects of their
gene knockdowns on pharyngeal pumping with or without D20
treatment (Figure 4A). Among the 26 receptor tyrosine kinases,
RNAi exposure of only one resulted in an interaction insensitive to
D20 treatment—that of the VEGF-related receptor encoded by
ver-3 (Figure 4A). C. elegans subjected to ver-3 RNAi exhibit an
elevated pharyngeal pumping phenotype relative to vector control-
treated animals, thus mimicking the effects of D20 treatment
(Figure 4A). While some of the other kinase knockdowns elevated
the feeding rate, they all remained sensitive to further modulation
by D20. For example, while F09A5.2 RNAi and frk-1 RNAi each
caused increased pumping relative to RNAi vector control, D20
treatment further increased pumping rates of these RNAi-treated
animals (Figure 4A). Thus, the resistance of ver-3 mutants to
further enhancement of feeding by D20 was not simply due to an
upper physiological limit on the pumping rate. Because pharyn-
geal pumping is regulated by the nervous system and RNAi is
sometimes ineffective at gene knockdown, particularly in the C.
elegans nervous system [43], it is possible that some of the intended
gene products could not be sufficiently knocked down by our
RNAi strategy. However, using RNAi to knock down gene
expression products of each of ver-3, ver-2, egl-15, and vab-1, all of
which have reported nervous system expressions (Table S3), led to
effects on pharyngeal pumping that were similar to those obtained
when we examined mutants in each of these genes (Figure 4C).
Thus, the combination of in vitro binding assays and patterns of
phenotypic interactions in vivo strongly supported the notion that
D20 mediates its feeding increasing effects in a ver-3–dependent
mechanism.
To further compare the pharmacological parallels between Flt-3
inhibitors and pharyngeal pumping, we tested a known Flt-3
receptor inhibitor (59-fluoroindirubinoxime: 5-flurox, Figure 4B)
for its effects on pharyngeal pumping. D20 induces a dose-
dependent increase in the pharyngeal pumping rate with an EC50
of 600 nM (Figure 4B). Similarly, 5-flurox mimicked the dose-
dependent effect of D20 with an EC50 of 40 nM (Figure 4B). The
increased in vivo efficacy correlates with the measured in vitro
activities of the Flt-3 receptor for D20 (Ki = 165 nM) and 5-flurox
(IC50 = 15 nM) [44]. Finally, joint D20 and 5-flurox treatment did
not increase pharyngeal pumping rate beyond that seen by
individual compound treatments (Figure S5A). These combined
results suggest that a target pharmacologically similar to the Flt-3
receptor exists in C. elegans to regulate pharyngeal pumping.
To verify the RNAi results and further ascertain that D20 and
5-flurox elicit similar effects on C. elegans feeding behavior, we
focused on ver-3 and its closest family members, ver-1, ver-2, ver-4,
and egl-15. Similar to the RNAi results, mutants in either ver-2 or
ver-3 exhibited elevated rates of pharyngeal pumping, while those
of ver-1 and ver-4 resembled wild-type, and egl-15 mutants had
reduced rates of pumping (Figure 4C). As with D20, the elevated
feeding rates of ver-3 mutants were insensitive to further increase
with 5-flurox treatment (Figure 4C). In contrast, treatment of egl-
15, ver-1, and ver-4 receptor mutants with either D20 or 5-flurox
led to similar increases in pumping rate despite different basal
pumping rates of these mutants. Treatment of the ver-2 mutants,
whose basal pumping rate was increased relative to WT, returned
to untreated, WT rates with either compound, recapitulating the
effect observed when D20 treatment was combined with ver-
2(RNAi) (Figure 4A). The reason for this antagonistic relationship is
unclear to us but may reflect a dependence of D20’s feeding
elevated phenotype on intact ver-2 signaling, perhaps due to a
compensatory mechanism between the different receptors. These
observations support the notion that the tyrosine kinase receptor
VER-3 is pharmacologically orthologous to the human Flt-3
receptor and responsible for D20’s feeding phenotype.
SEA predictions may prove informative for finding mechanistic
targets in C. elegans even if they fail to modulate the predicted
mammalian targets. This appears to be the case for K9, an analog
of D20 also predicted to inhibit Flt-3 kinase (Table S1, Figure 4C).
K9-treated C. elegans resembled D20-treated animals in the dose-
dependent increase in feeding rate observed (Figure 4D). In
addition, K9 exhibited the same genetic interactions as D20- and
5-flurox–treated animals: wild-type, egl-15, ver-1, and ver-4 mutants
all exhibited elevated pharyngeal pumping (Figure 4C); ver-3
mutants were insensitive to treatment; and the fast pumping ver-2
mutant reverted to the wild-type rate upon K9 treatment.
Therefore, the similarity of the pharmacological response between
Figure 3. Several compounds with predicted and confirmed
human targets increase pharyngeal pumping. (A) Wild-type C.
elegans were cultured on media supplemented with either 0.1% DMSO
(vehicle control) or 10 mM of each compound. (B) The effects of the
compounds on the pharyngeal pumping rate when exposed for
differing developmental periods was evaluated for C. elegans exposed
to each 10 uM of each compound during different times: L1 to L4 (2 d
at 20uC), L1 to gravid adult (3 d at 20uC, and naı̈ve day 1 gravid adults
exposed to B16, F15, and D20 for 1 h, H6 for 16 h). The pharyngeal
pumping rate of 10–13 animals per condition was quantified. Error bars
represent the standard deviation. *p,0.01: ANOVA, Dunnett’s multiple
comparisons test. In (B) gravid adults exposed to H6 for 16 h was
compared to DMSO 16 h (t test: two tailed *p,0.01).
doi:10.1371/journal.pbio.1001712.g003
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Figure 4. D20 antagonizes a VER-3–dependent pathway to induce pharyngeal pumping. (A) Animals were cultured on different RNAi
clones in media supplemented with either 0.05% DMSO or 5 mM D20. Sequences are arranged based on their BLASTp similarity to the human FLT-3
receptor from most similar (left) to least similar (right). Error bars represent the s.e.m. **p,0.001, *p,0.01 (D20 versus DMSO): two-tailed t test. (B)
Pharyngeal pumping rates of wild-type C. elegans treated with serial 3-fold dilutions of 5-flurox or D20. (C) The pharyngeal pumping rates of wild-
type, egl-15(n484), ver-1(ok1738), ver-2(ok897), ver-3(ok891), and ver-4(ok1079) mutant animals cultured on 0.1% DMSO, 10 mM D20, 10 mM K9, or 2 mM
5-flurox. Error bars represent the standard deviation. Significance levels: **p,0.001 were determined by one-way ANOVA using Bonferroni’s multiple
Prediction & Testing of C. elegans Feeding Targets
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the C. elegans ver-3 and the human Flt-3 receptors, while substantial,
is clearly not identical.
Based on the SEA and in vitro binding data, we next examined
the possibility that an oxytocin receptor-like system may underlie
the feeding regulatory effects of F15 (Figure 2). The oxytocin
receptor system modulates mammalian feeding [45–47], but the
existence of a C. elegans oxytocin receptor ortholog with a role in
feeding regulation has not been defined. Both F15 and a
comparison test. (D) C. elegans were treated with serial 3-fold dilutions of K9 and the pharyngeal pumping rate was quantified at each dose. Error bars
represent the s.e.m. In (A–D) 10–20 animals were evaluated per condition.
doi:10.1371/journal.pbio.1001712.g004
Figure 5. Identification of C. elegans GPCR-regulated feeding pathways that are pharmacologically orthologous to their human
targets. (A) Wild-type C. elegans treated with serial 3-fold dilutions of either F15 or L-371257. Error bars represent the standard error of the mean. (B)
Wild-type, ntr-1(ok2780), gnrr-1(ok238), gnrr-2(tm4867), or gnrr-3(tm4152) mutant animals cultured on either 0.1% DMSO, 10 mM F15, 100 nM L-
371257, or 200 nM SB222200. (C) Wild-type C. elegans cultured on E. coli expressing either tkr-1 RNAi or vector control, then treated with either 0.1%
DMSO,10 mM H6, 10 mM F15, or 200 nM SB222200. (D) Wild-type, mgl-1(tm1811), and mgl-2(tm355) mutant C. elegans cultured on media containing
either 0.1% DMSO, 10 mM B16, 10 mM F15, or 2 mM MMPIP. Error bars represent the standard deviation. (A–D) The mean pharyngeal pumping rate of
10–20 C. elegans per condition are shown. Significance levels: **p,0.001, *p,0.05 were determined by one-way ANOVA using Bonferroni’s multiple
comparison test.
doi:10.1371/journal.pbio.1001712.g005
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structurally independent oxytocin receptor antagonist L-371257
exhibited dose-dependent increases in C. elegans pharyngeal
pumping with in vivo EC50’s of 400 and 10 nM, respectively
(Figure 5A). Like D20 and 5-flurox, their in vivo C. elegans efficacies
parallel their in vitro affinities toward the human receptor (Oxtr Ki’s
for F15, 1.6 mM and for L-371257, 4.6 nM) [48]. Furthermore,
simultaneous treatment with F15 and L-371257 did not further
elevate pumping (Figure S5B), suggesting the existence of a target
with pharmacological similarity to the human oxytocin receptor
that regulates feeding.
BLAST comparisons suggest multiple C. elegans sequences with
similarity to the human oxytocin receptor. These include an
oxytocin/vasopressin-like receptor NTR-1 (T07D10.2) that mod-
ulates male mating behavior [49] and associative learning [50], a
tachykinin receptor-like protein TKR-1, and three related
receptors (GNRR-1, -2, -3) (Table S3). We examined the
pharyngeal pumping rates in ntr-1 and the gnrr-1, -2, and -3
mutants (Figure 5B) and animals treated with tkr-1 RNAi
(Figure 5C). Both ntr-1 and gnrr-2 mutants exhibited wild-type
feeding rates and were sensitive to F15- and L-371257-induced
pharyngeal pumping increases. Both gnrr-1 and -3 mutants
(Figure 5B) as well as tkr-1(RNAi) animals (Figure 5C) exhibited
elevated pumping in the absence of compound treatment.
However, only the pharyngeal pumping rate of the gnrr-1 mutants
was resistant to further increase by F15 and oxytocin-antagonizing
L-371257 treatments (Figure 5B,C). Turning to the tachykinin
system, each of wild-type, ntr-1, gnrr-1, -2, and -3 mutants
responded with increased feeding on treatment with SB222200,
a high-affinity human tachykinin receptor antagonist (Figure 5C).
In contrast to their F15 sensitivity, tkr-1(RNAi)–treated animals
were indeed insensitive to the pharyngeal pumping rate increases
elicited by either SB222200 or H6 treatment (Figure 5C), a
compound identified in our C. elegans phenotypic screen and shown
in vitro to act on a human tachykinin receptor (Figure 2). Wild-type
H6-dosed animals were insensitive to SB222200-induced feeding
increase (Figure S5C) consistent with their in vitro activities as
tachykinin receptor antagonists. Together these results indicate
that a tachykinin-like and an oxytocin-like receptor pathway
function in parallel to regulate pharyngeal pumping in C. elegans.
Despite relative similarities in sequence and feeding phenotype,
gnrr-1 and tkr-1 mutants were differentiated by their antagonists
and pharmacologically linked to the human oxytocin and
tachykinin receptors, based on responsiveness to F15/L-371257
and H6/SB222200, respectively.
Finally we tested whether B16, the mammalian mGluR-8
inhibitor, regulates the pharyngeal pumping rate through any of
the C. elegans metabotropic glutamate receptors. The C. elegans
genome encodes three orthologs of human mGluR-8: mgl-1, -2,
and -3 [51]. These receptors are expressed in the C. elegans nervous
system and regulate diverse aspects of C. elegans behavior and
physiology, but have not previously been implicated in feeding
[52]. We found that mgl-2 but not mgl-1 mutant animals exhibited
an elevated pharyngeal pumping rate in the absence of B16
treatment (Figure 5D). The elevated feeding of mgl-2 mutants
resembled that of WT animals treated with B16, and that of
animals treated with MMPIP [53], a human mGluR-7 allosteric
antagonist (IC50’s, 26–220 nM) structurally distinct from B16
(Figure 5D). Combined treatment of wild-type animals with B16
and MMPIP resulted in no further increase over either alone
(Figure S5D). The pharyngeal pumping rate of mgl-2 mutant
animals, unlike both WT and mgl-1 mutant animals, was
unaffected by treatment with either B16 or MMPIP, consistent
with the notion that both agents mediate their feeding phenotype
though inhibition of MGL-2. Similar to WT and mgl-1 mutants,
mgl-2 mutant animals further elevated pumping when treated with
the Oxtr/GNRR-1 antagonist F15 (Figure 5D). The additive effect
of F15 on the mgl-2 mutants’ pharyngeal pumping rate
distinguishes its underlying biological mechanism from that of
the mGluR/mgl-2 antagonists.
The Regulatory Relationships of the Newly Identified
Feeding Pathways
To further examine the in vivo specificity of the compound-
induced feeding phenotypes and determine whether each target
regulates feeding independently of one another, we examined the
feeding phenotypes of all possible binary combinations of
compounds with the high pumping mutants identified by this
study (Table S4). The resulting 54-interaction matrix (Figure 6A)
classifies interactions between compounds and mutants based on
the sensitivity of a mutant to a compound’s effect on pharyngeal
pumping. Considering that relative to wild-type animals on vehicle
control each of the gene knockdowns and compound treatments
individually were sufficient to cause feeding increases, two patterns
of interactions were expected: interactions where the feeding
increasing effects are additive, representing likely parallel mech-
anisms of actions, and those that are nonadditive, suggesting a
single regulatory pathway. Pharyngeal pumping rates that
exceeded those observed in the vehicle-treated mutant controls
are classified as additive. For example, both H6 and SB222200
increase the pharyngeal pumping rates of mgl-2, ver-3, gnrr-1, ver-2,
and gnrr-3 mutants, a series of additive interactions, but not that of
animals treated with tkr-1 RNAi, a genetic inactivation in their
common target.
We also noted 10 interactions in which elevated pumping rates
of specific mutants were lowered upon compound treatment. For
instance, while each of D20, K9, and 5-flurox treatments alone, as
does inactivation of ver-2, elevate feeding rates in wild-type and in
many mutant backgrounds, treatment of ver-2 mutants with each
of these compounds lowers feeding (Figure 4C, Figure 6A). Similar
antagonistic patterns were also seen, for example, when ver-3
mutants were treated with the Oxtr antagonists F15 and L-
371257. While the precise reasons for antagonistic interactions are
not known, one likely possibility is that distinct signaling pathways
normally act in compensatory manners that are revealed by the
simultaneous inhibition of both of these pathways.
Strikingly, we noted that in all cases where compounds share a
common target, for example F15, L-371257, and the oxytocin
receptor, both compounds exhibited identical interactions, unique
to each compound pair across the mutant series. This includes
additive, nonadditive, and antagonist interactions. This result
strongly supports the hypothesis that the compounds share a
common in vivo target identified by this study that drives the
feeding phenotype. Beyond specificity, this matrix also indicates a
higher level pathway organization of these mutants (Figure 6A).
Both antagonists of the mgl-2 pathway (B16 and MMPIP) and
VER-3 inhibitors (D20, K9, and 5-flurox) interact nonadditively
and reciprocally with ver-3 and mgl-2 mutants, indicating that these
gene products may act in a common pathway. However, the
additive effect of B16/MMPIP versus the antagonistic phenotypic
effect of D20/K9/5-flurox activity on gnrr-1 mutants is consistent
with their targets being distinct entities. In addition, GNRR-1
antagonists (F15 and L-371257) interact nonadditively with ver-2
mutants and antagonistically with ver-3, recapitulating the
antagonistic interaction of VER-3 inhibitors with ver-2 mutants
(Figure 4C, Figure 6A). This indicates that a second feeding
regulatory pathway combines GNRR-1 and VER-2 signaling.
To evaluate whether the chemical-genetic epistasis interactions
observed were the result of pharmacological peculiarities or could
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be confirmed by standard genetic epistasis tests, we tested genetic
interactions in the implied mgl-2/ver-3 and ver-2/gnrr-1 pathways.
The feeding rate of ver-3 mutants was insensitive to effects of mgl-
2(RNAi), but was reduced by ver-2(RNAi) (Figure 5B). Mgl-2(RNAi)
interacted additively with gnrr-1 mutants to increase the pumping
rate, and ver-3(RNAi) antagonized the feeding increasing effects of
the gnrr-1 mutation (Figure 5B). Ver-2(RNAi) interacted nonaddi-
tively with the gnrr-1 mutants and was antagonistic to mgl-2
mutants (Figure 5B). Similar interactions between gnrr-1 mutants
and ver-3(RNAi), ver-2(RNAi), and mgl-2(RNAi) were observed by
Figure 6. Interaction matrix of all binary combinations of compounds and gene knockdowns that individually increase pharyngeal
pumping. (A) The differences in the pumping rates of compound-treated versus vehicle (0.1% DMSO) treatment on each genetic background for all
pair-wise combinations of compounds and mutants were evaluated. Compound concentrations used were 10 mM for B16, D20, K9, F15, and H6;
200 nM for L-371257 and SB 222200; and 2 mM for MMPIP, 5-flurox. The predicted compound–target interactions are outlined in yellow. Red- and
blue-labeled interactions indicate pumping rates significantly different (ANOVA, p,0.05 Dunnett’s multiple comparison test) from the corresponding
vehicle control-treated mutant. (B) The implied genetic interactions on pharyngeal pumping of mgl-2, ver-2, ver-3, and gnrr-1 mutants assayed by
mutant–RNAi combinations. Twelve animals per condition were analyzed. Error bars represent 1 standard deviation. * p,0.001 one-way ANOVA
using Bonferroni’s multiple comparison test.
doi:10.1371/journal.pbio.1001712.g006
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measuring pumping over longer intervals by time lapse micros-
copy (Figure S6). These results indicate that the chemical-genetic
interactions observed in this study accurately predict the
interactions of loss-of-function perturbation combinations on the
pharyngeal pumping rate. As in chemical-genetic interactions,
examination of mutant combinations also indicated that mgl-2/ver-
3 and ver-2/gnrr-1 function in parallel pathways but with significant
crosstalk in regulating the pharyngeal pumping rate.
Discussion
Whole organism phenotypic screens retain key advantages of
classical pharmacological approaches, such as the discovery of
compounds that are biologically active and that alter physiolog-
ically intact, integrated circuits without predisposed conceptions as
to which circuits should be targeted. To prove biologically
informative, this forward pharmacological approach requires the
determination of in vivo molecular targets as well as the mode of
action by which the phenotype is modulated [54]. Five key
observations emerge from this study. First, by chemoinformatic
inference, targets may be rapidly prioritized for experimental
testing on isolated receptors in vitro. Whereas this method did not
always succeed, the confirmation of the predicted targets was high
enough, at 43%, to be practical. Second, as the identified targets
are overwhelmingly mammalian, the ease of phenotypic screening
strategies in C. elegans can be linked to identification of human-
relevant targets. Third, in a model system such as C. elegans, the
relationships of orthologous targets to in vivo phenotypes can be
parsed by applying the rationale of genetic epistasis analysis. This
is critical for unambiguous in vivo establishment of mechanisms of
action, as in vitro activities of even highly characterized compounds
are only suggestive of the in vivo efficacy targets. Fourth, despite
significant differences in primary sequence identity of the targets,
the in vivo efficacy in C. elegans can reflect the in vitro activity against
human targets. Finally, the chemical-genetic interactions described
in this study illuminate four previously uncharacterized, parallel
molecular targets that regulate food intake. Together, these
findings demonstrate an experimental and computational path
from phenotypic screens in C. elegans to the discovery of human-
relevant targets and elucidation of mechanisms of actions of newly
identified compounds in C. elegans.
Most drugs interact with multiple targets in vivo [41], which can
confound the assignment of phenotypic effects to particular
targets. This can be especially true of compounds emerging from
screening campaigns prior to any efforts aimed at optimizing the
potential specificities of compounds. An advantage of a pharma-
cological approach in C. elegans is that genetic perturbations can
test target engagement in vivo. Identifying a chemical-genetic
epistatic interaction does not imply that a given compound has
absolute specificity for a particular target in a biological system.
However, the epistasis interaction does confirm that the
compound induces a particular phenotype specifically through
its interaction with the pathway defined by the genetic perturba-
tion. Thus, in a manner similar to classical double mutant analysis,
chemical and genetic interactions are combined to interrogate the
pharmacological relevance of hypothesized target interactions to
specific phenotypes.
Our findings suggest that there is a substantial pharmacological
intersection between mammals and C. elegans. These results
indicate that a C. elegans phenotypic screen can lead to
identification of compounds that are sufficiently similar to the
mammalian pharmacopeia to allow for prediction and confirma-
tion of their interactions with mammalian targets. In turn,
evolutionary conservation of these targets, in both sequence and
ligand recognition, makes it possible to accurately predict the C.
elegans target whose perturbation results in the phenotype. It could
have easily been the case that the compounds emerging from a C.
elegans screen are so diverse as to belie prediction of targets, and
that the C. elegans phenotypes could be irrelevant to the human
target space, or could reflect new targets not previously seen. As
such, it may be astonishing that this approach worked at all. In
fact, 79 of 84 active compounds could be chemoinformatically
linked to human targets, suggesting that even a diversity library
retains substantial and, for our purposes, highly useful biases
towards previously ‘‘liganded’’ targets. Moreover, whereas these in
vitro mammalian targets need have no relevance for C. elegans in vivo
pharmacology, for compounds with confirmed activity in vitro,
orthologous targets were indeed found to mediate their C. elegans
phenotypes.
Whether the specific compounds identified from the C. elegans
screen act on mammalian feeding and regulatory systems remains
to be determined. However, there are already some hints that
functionally related circuits modulate feeding behavior in both
mammals and C. elegans. For instance, several independent studies
in chickens, mice, and rats indicate that administration of oxytocin
reduces food intake [55]. Oxytocin appears to be a target of satiety
signals since a lipid-related signal, oleoylethanolamide, positively
requires intact hypothalamic oxytocin signaling to mediate its
anorexigenic effects [45]. Conversely, hyperphagia associated with
a high-fat diet requires synaptotagmin-4–mediated suppression of
oxytocin vesicle exocytosis [46]. Furthermore, a key function of
neurons of the hypothalamus that stimulate feeding involves the
inhibition of a separate population of oxytocin neurons [47]. Thus,
analogous to C. elegans gnrr-1, signaling through the oxytocin
receptor is a negative regulator of food intake in mice. Similarly,
central administration of substance P, a TKR ligand, inhibits
feeding in chicks [56], consistent with the negative feeding
regulatory role of the TKR-1 in C. elegans. While the Flt-3
receptor has no known role in the mammalian nervous system,
closely related growth factor receptors, such as the platelet-derived
growth factor–b (PDGF-b) receptor, are expressed in the
hypothalamus, and administration of PDGF-b depresses food
intake and anti-PDGF-b antibodies elevate food intake in rats
[57]. This resembles our observation that loss-of-function in a C.
elegans receptor tyrosine kinase (ver-3) through either mutation or
pharmacological inhibition elevates pharyngeal pumping. These
targets may thus have ancient evolutionary origins in the
regulation of feeding behavior.
Key weaknesses of our approach merit discussion. First, whereas
it is comforting that we can predict targets for most biologically
active synthetic compounds even in a ‘‘diversity’’ library, this also
reflects the restricted chemical-target space in which the field is
working. A library composed of genuinely novel chemotypes might
be more likely to illuminate unprecedented targets, a widely
desired goal of the field. On the other hand, any such truly diverse
library risks missing that small part of chemical space that is
relevant to terrestrial biology, the bias towards which is, after all, a
pragmatic advantage of the current libraries [58]. Second, even
within this restricted ligand–target space, the chemoinformatic
linkage was far from perfect, and about half of the tested
compounds remain unlinked to predicted targets. While the
inferential computational approach cannot replace experiment, it
is a rapid, comprehensive, and quantitative assessment of
biologically active small molecules with unknown mechanism.
These predictions generate testable hypotheses with regards to in
vivo function. Third, while for feeding, the in vitro and in vivo data
provided a compelling case for mechanisms of actions of F15, H6,
B16, and D20, it remains to be determined whether these
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compounds also act on as-of-yet undetermined molecular path-
ways to alter other biological processes in C. elegans. Finally, while
the link between compounds, targets, and C. elegans phenotypes
now seems strong for several of the active compounds, linkage
between C. elegans and mammalian in vivo pharmacology remains
to be drawn.
In summary, whereas chemoinformatic linkage retains impor-
tant liabilities, its success rate here and in earlier studies [37–
39,41] is high enough to be pragmatic for target hypothesis testing.
Similarly, despite critical differences between C. elegans and
mammals, some of them target-based, some biology-based, the
targets and ligand networks for a substantial number of small
molecules are conserved enough to allow target and phenotypic
association across phyla. We envision that such chemical-genetic
epistasis maps could be extended to saturation mapping of the
pharmacological target networks underlying feeding regulation
and other processes in C. elegans. The amenability of C. elegans to
genetic manipulation and pharmacological screening may find
broad utility as a means to identify new small molecules with
interesting phenotypes and human-relevant targets.
Materials and Methods
Chemicals
I10, G7, A5, and L15 were purchased from Chembridge. A15,
D20, K9, G6, L10, H6, and F14 were purchased from SPECS.
B16, N10, and F15 were purchased from Princeton Biomolecular
Research. J16 was purchased from TimTec. MMPIP hydrochlo-
ride, SB222200, 100 nM L-371257, and 5-fluoroindirubinoxime
were purchased from Tocris Biosciences. All other chemicals were
purchased from Sigma.
Computational Analysis
We computationally screened 84 phenotypically active com-
pounds against molecular target panels from the ChEMBL
database (http://www.ebi.ac.uk/chembl) using the Similarity
Ensemble Approach (SEA) [37,39] operating on 1,024-bit folded
Scitegic ECFP_4 fingerprints [59] and Tanimoto coefficients as
previously described [37].
For the target panel, we first used ChEMBL_7 (released
November 11, 2010) and later moved to an updated 2,482
molecular target panel derived from ChEMBL_11 (released
August 9, 2011). We filtered reference ligands by molecular
weight (#1,000 Da) and by reported affinity (#10 mM), and then
subjected all ligand structures to cleaning, standardization, and de-
duplication as before [39].
In Vitro Compound Assays against Mammalian Targets
Tachykinin, ghrelin, and calcium-sensing receptor activity were
measured using a cell-based Ca flux assay by Multispan, Inc.
(Hayward, California). Cholescystokinin A and B receptors were
assayed for effects on cAMP production, and nicotinic acid
receptor activity was measured in a cell-based assay of forskolin-
stimulated cAMP production by Multispan, Inc. Calcium-sensing
receptor, PP2A phosphatase activity assays were performed by
CEREP (Celle l’Evescault, France) using PP2A from human
erythrocytes. Phospholipase C from Bacillus cereus was assayed by
CEREP, Inc. using glycero-phosphatidyl ethanolamine as a
substrate, monitoring diacyl glycerol production. Radioligand
binding assays for PPAR-a, c, d and the androgen receptor were
performed by CEREP, Inc. CARNA Biosciences (Kobe, Japan)
performed in vitro kinase activity assays using recombinant catalytic
domains and measured phosphorylation of an Src-derived peptide
for Flt-3 and phosphatidyl inositol for PI3KCA. Radioligand
binding assays for the oxytocin receptor, D4 dopamine receptor,
cannabinoid CB2 receptor, and angiotensin type I and II receptors
were performed as described previously, as were cell-based activity
assays for mGluR 1a, 2, 4, 5, 6, and 8 [60–62].
C. elegans Strains
Strains containing mgl-1(tm1811) X, mgl-2(tm355) I, gnrr-
2(tm4867) V, and gnrr-3(tm4152) X were obtained from the
National Bioresource Project for the Nematode courtesy of
Dr. S. Mitani at Tokyo Women’s Medical University School of
Medicine. Strains containing gnrr-1(ok238) I, ntr-1(ok2780) I, egl-
15(n484) X, ver-1(ok1738) III, ver-2(ok897) I, ver-3(ok891) X, and
ver-4(ok1079) X were obtained from the C. elegans Genetics
Center, which is funded by the NIH National Center for
Research Resources (NCRR). N2 (Bristol) strain was utilized as
a reference wild-type strain. Strains were outcrossed 4 times to
the wild-type background. Unless described otherwise, strains
were cultivated on NGM-agar plates seeded with E. coli OP-50
as described [63].
RNA Interference
Synchronized first larval stage C. elegans were cultured for 3 d at
20uC on a lawn of HT115 E. coli induced with IPTG to express
double-stranded RNAi as described [64].
Pharyngeal Pumping Assay
Compounds at 1,0006 stock concentrations (0.1–10 mM) in
DMSO or an equal volume of DMSO were diluted in a
suspension of E. coli OP-50 (100 ml of a 36concentrated overnight
culture in LB broth) and absorbed as a single drop onto 3.5 cm
plates containing 2.5 ml of NGM agar forming a well-defined
lawn of bacteria. For developmental exposures, 20–30 synchro-
nized first larval stage C. elegans derived from alkaline
hypochlorite treatment of gravid adults were applied to the
preseeded plates and cultured until assay at mid-L4 stage (2 d,
20uC) or as day 1 gravid adults (3 d, 20uC). For naı̈ve adult
exposures, synchronized first larval stage animals were cultured
on NGM-agar plates seeded with E. coli OP-50 for 3 d at 20uC,
then transferred to assay plates, and pumping was assayed 1 to
16 h later. Comparisons between vehicle-treated and com-
pound-treated animals were always performed between animals
at the same developmental stage and same exposure time.
Pharyngeal pumping was counted by live observation at 115–
2006 magnification using a stereo microscope and recorded at
10 s intervals using a manually controlled digital cell counter.
Alternatively, C. elegans pumping was recorded for longer
intervals (30–60 s) using bright-field time-lapse microscopy at
1206 magnification with a 20 images per second acquisition
rate. The resulting movies were analyzed manually at a
playback rate of 10 images per second.
Statistics
Significance was determined by one-way ANOVA applying a
Dunnett’s posttest when comparing multiple treatments to a single
control and a Bonferroni posttest when comparing the more than
two treatments against one another. For pairwise nonrepeated
measured comparisons, a student’s t test was used. To express data
as a percentage of control, the pumping rates of compound-treated
animals were divided by the mean pumping rate of the DMSO-
treated wild-type animals measured in the same experiment, unless
indicated otherwise. Error bars on the control samples indicate the
variation around that mean, which is utilized in all statistical
calculations.
Prediction & Testing of C. elegans Feeding Targets
PLOS Biology | www.plosbiology.org 11 November 2013 | Volume 11 | Issue 11 | e1001712
Supporting Information
Figure S1 Dose-response measurements that validate
SEA predictions for GPCRs. (A) B16 inhibits rat mGluR-8
activity in CHO cells that were stimulated with 1 mM L-AP4
agonist. Error bars represent the s.e.m. of eight measurements.
One-way ANOVA (Bonferonni) at concentrations of
B16.361026 M indicate the responses are significant
(p,0.001). (B) Inhibition of 3H-oxytocin binding to the human
oxytocin receptor by unlabeled oxytocin peptide (black squares) or
F15 (red triangles). (C) H6 inhibits the calcium flux induced in cells
expressing the human tachykinin-1 receptor, stimulated by
neurokinin-1 peptide. Error bars represent the s.d. of three
measurements. One-way ANOVA (Bonferroni) at concentrations
.1026.4 M indicate the responses are significant (p,0.01). (D)
Inhibition of 3H-risperidone binding to the human dopamine D4
receptor by chlorpromazine (black squares) or G7 (red triangles) at
concentrations of G7.1026.4 M indicates the response is
significant: p,0.001 ANOVA (Bonferroni).
(TIF)
Figure S2 Dose-dependent inhibitory activity for com-
pounds predicted by SEA to inhibit kinases. (A–B) Varying
concentrations of J6 and L10 were incubated with full-length
recombinant human PI3KCA and ATP (50 mM) for 5 h and the
phosphorylation level of the substrate phosphatidylinositol was
measured. (A) L10 inhibition of PI3-kinase p110a is significant at
concentrations .161026 M (p,0.05, t test). (B) J6 inhibition of
PI3-kinase p110a is significant at concentrations .161026 M
(p,0.05, t test). (C) D20 inhibition of flt-3 receptor catalytic
domain activity. Varying concentrations of D20 were incubated
with recombinant human Flt-3 receptor catalytic domain (amino
acids 564–993), 100 mM ATP, and the phosphorylation of srctide
peptide substrate was measured after 1 h at each concentration of
D20. Inhibition at concentrations .161027 M is significant
(p,0.01, t test). Error bars represent the s.d. of two replicates.
(TIF)
Figure S3 Dose-response relationships for compounds
that bind nuclear hormone receptors. (A) 3H-Rosiglitazone
binding to human PPAR-c in the presence of varying concentra-
tions of I10. (B) 3H-Mibolerone binding to the human androgen
receptor in the presence of varying concentrations of G6. Error
bars represent the standard deviation of two replicates.
(TIF)
Figure S4 Measurement of the pharyngeal pumping
effects of the compounds by time lapse microscopy. C.
elegans were cultured for 3 d from L1 larvae in the presence of
either 10 mM B16, H6, D20, and F15 or 0.1% DMSO as the
vehicle control. Pharyngeal pumping over 60 s intervals was
measured in time lapse recordings of at least 60 s in duration. A
comparison with the pumping rates measured over 10 s (6-fold
extrapolated) by real-time direct observation of the same
populations of animals is presented. Real-time, 10 s interval
manual counting involves a systematic underestimation of
pumping across all conditions, however the relative ratios are
similar. Ten animals were measured per condition. Error bars
represent the standard deviation. *p,0.001 one-way ANOVA,
Bonferroni posttest.
(TIF)
Figure S5 Effect on pharyngeal pumping of combina-
tions of compounds that target the same human
receptor. (A) C. elegans were cultured with DMSO (0.2%),
10 mM D20, 1 mM 5-flurox, or a combination of 10 mM D20 and
1 mM 5-flurox. (B) C. elegans were cultured with DMSO (0.2%),
10 mM F15, 200 nM L-371257, or a combination of 10 mM F15
and 200 nM L-371257. (C) C. elegans were cultured with DMSO
(0.2%), 10 mM H6, 200 nM SB222200, or a combination of
10 mM H6 and 200 nM SB222200. (D) C. elegans were cultured
with DMSO (0.2%), 10 mM B16, 2 mM MMPIP, or a combina-
tion of 10 mM H6 and 2 mM MMPIP. In (A–D) 12 animals per
condition were counted. Error bars represent the standard
deviation. *p,0.001 ANOVA, Dunnett’s posttest.
(TIF)
Figure S6 Genetic interactions of gnrr-1 mutants quan-
tified by time lapse measurements. Wild-type and gnrr-1
mutants were cultured on bacteria expressing double-stranded
RNA targeting mgl-2, ver-3, ver-2, or the RNAi expression vector
control. Pharyngeal pumping of 10 animals per condition for 30 s
intervals was recorded by time-lapse microscopy. The color
scheme of the figure matches that of Figure 5. Error bars represent
the standard deviation. ns, not specific, p.0.05, *p,0.05,
**p,0.01 ANOVA, Bonferroni posttest.
(TIF)
Movie S1 C. elegans treated with 10 mM F15.
(MP4)
Movie S2 C. elegans treated with 10 mM B16.
(MP4)
Movie S3 C. elegans treated with 10 mM D20.
(MP4)
Movie S4 C. elegans treated with 10 mM H6.
(MP4)
Movie S5 C. elegans treated with 0.1% DMSO.
(MP4)
Table S1 Target predictions that could not be con-
firmed in vitro.
(T )
Table S2 Activity of 10 mM B16 on human metabotropic
glutamate receptors.
(DOCX)
Table S3 Known expression patterns of C. elegans
homologs used in the manuscript and their sequence
comparisons to human targets.
(DOCX)
Table S4 Epistasis data used to construct interaction
matrix in Figure 6A.
(DOC)
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